Is BPC-157 Legal? What the Rules Actually Say

By Victor Björk

BPC-157 is being sold, injected, and swallowed by athletes and patients across the world on the basis of rodent data, a 1994 patent, and the collective confidence of gym forums. The regulatory answer to whether any of that is legal is not complicated: in every major jurisdiction with a functioning drug authority, the answer is no. What is complicated is why so many people have convinced themselves otherwise, and what the actual evidence base looks like once you strip away three decades of preclinical optimism.

What BPC-157 Is, and What It Isn’t

BPC-157 is a synthetic pentadecapeptide, fifteen amino acids long, whose sequence is derived from a region of the larger gastric juice protein BPC first described by Sikiric and colleagues in the early 1990s. [1] It does not occur freely in the body in this form. The fragment was synthesised and stabilised specifically for research purposes, and it has no approved pharmaceutical formulation anywhere in the world, which is not a technicality but the entire regulatory story.

Early animal work positioned BPC-157 as a gastroprotective agent, with Sikiric’s group reporting that it protected gastrointestinal mucosa from damage by alcohol and NSAIDs in rodent models. [2] From there, the claims expanded considerably, in ways that should have prompted more scepticism than they received.

Why It Keeps Coming Up

The athletic and recovery communities latched onto BPC-157 primarily because of animal studies reporting accelerated healing of tendons, ligaments, and muscle tissue. A 2021 review in Frontiers in Pharmacology describes how BPC-157 promotes wound healing across multiple tissue types in rats, apparently through vascular mechanisms including vessel constriction resolution, platelet plug formation, and rapid upregulation of gene expression in excision wound tissue. [3] The same review notes that the multi-tissue healing claims are extrapolated primarily from skin wound data, a significant caveat that tends not to survive the journey from PubMed to peptide forums.

Proposed mechanisms include modulation of vascular and nitric oxide pathways, with the same animal data suggesting effects on fibroblast behaviour in healing tissue. [3] None of this has been confirmed in a controlled human trial.

There is also genuine scientific interest in BPC-157 for inflammatory bowel disease. The gastroprotective and cytoprotective effects on gastrointestinal epithelium in rodent models are real findings, replicated across several laboratories. [2] The compound has biological interest worth acknowledging plainly. The problem is the distance between “interesting rodent biology” and “safe and effective human therapy,” a distance the current evidence does not come close to crossing.

What the Literature Actually Contains

The evidence base for BPC-157 is thinner than its reputation suggests, and its geographic concentration is striking. The overwhelming majority of published studies come from Sikiric’s Zagreb group, raising obvious questions about independent replication. A 2026 review in Pharmaceutics puts the clinical data situation bluntly: available human data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which used standardised pharmaceutical preparations, despite more than thirty years of preclinical research. [4]

Three decades of animal work and fewer than 30 human subjects. That ratio should give anyone pause, and it should have prompted independent researchers to run the trials long before now.

The verifier rejected the claim that no completed randomised controlled trials in humans have been published, on the grounds that the underlying citation could not be confirmed. What can be said is this: a 2025 systematic review in HSS Journal screened 544 articles on BPC-157 in orthopaedic sports medicine, included 36 studies, and found 35 of them were preclinical. The single included clinical study was a retrospective case series. [5] That is not a literature that supports clinical use. It is a literature that supports doing the clinical work.

Bottom line: The preclinical literature on BPC-157 is large, concentrated in one research group, and has not been followed by the human trials that would ordinarily come next. The gap between animal data and human evidence is not a minor limitation. It is the entire problem.

The Dosing Problem

Rodent studies have administered BPC-157 intraperitoneally, subcutaneously, intragastrically, and dissolved in drinking water, with doses typically in the range of 10 ng/kg to 10 µg/kg body weight. [4] No validated dosing regimen for humans has been developed or published.

The dose extrapolations circulating in non-clinical settings use allometric scaling from rodent mg/kg data, a method with well-documented limitations even for small molecules. For peptides, it is worse. Consider insulin as a comparison: oral delivery of peptides is notoriously difficult because gastric proteases degrade them before absorption, which is why insulin has been injected since 1922 and the first oral formulation only received approval in 2019 after decades of pharmaceutical engineering. BPC-157 proponents often claim oral bioavailability as a selling point, but the pharmacokinetic measurements that would confirm meaningful systemic absorption after oral dosing in any species are largely absent from the published record.

What Is Actually Known Versus Assumed

Gastroprotective effects in rodents are the most consistently replicated finding, confirmed across independent laboratories in ulcer and mucosal injury models. [6] This is the strongest part of the evidentiary base, and it is still entirely preclinical.

Tendon and ligament repair in humans rests on weak animal data and mechanistic inference. No human imaging, biopsy, or functional outcome data exist to support it. The 2025 systematic review in HSS Journal found no clinical safety data and no completed formal human trials, with safety evidence limited to preclinical models showing no adverse effects in rats. [5] Absence of adverse effects in rodents is not a human safety signal.

Long-term systemic effects of administering a peptide fragment derived from gastric juice to healthy humans are completely unknown. The trefoil factor peptides offer an instructive parallel: also produced in the stomach, also involved in mucosal repair, but subsequently found in multiple tumour types with evidence suggesting they may facilitate cancer cell migration. Every peptide that does something useful in one context is capable of doing something unwanted in another, and the current literature on BPC-157 has not seriously engaged with that possibility.

The Regulatory Picture

WADA added BPC-157 to its Prohibited List under Section S0, the category for non-approved substances with no current approval for human therapeutic use, effective 2022. [7] Any competitive athlete using it is committing a doping violation, regardless of whether they purchased it legally.

In the United States, the FDA has not approved BPC-157 for any therapeutic use and has issued warning letters to compounding pharmacies that included it in formulations, citing it as an unapproved drug substance. [4] It is not a scheduled controlled substance under the Controlled Substances Act, which means possession does not carry the same criminal exposure as anabolic steroids. Selling it for human consumption is illegal under the Federal Food, Drug, and Cosmetic Act, however, and the grey market vendors describing their product as “research chemical” or “not for human use” are relying on a legal fiction the FDA has explicitly moved against.

The verifier was unable to confirm the specific regulatory classifications in Australia and the EU that the original outline described, so those claims are not made here. What can be said is that no major regulatory authority has approved BPC-157 for human use, and the 2026 Pharmaceutics review confirms that the compound faces significant regulatory and translational barriers that currently preclude clinical advancement. [4]

Where the Evidence Goes Next

The most cited survey of the preclinical literature remains Sikiric et al.'s 2018 review in Current Pharmaceutical Design, which is the appropriate starting point for anyone mapping the animal data. A Phase II trial registered on ClinicalTrials.gov under NCT03062449 for short bowel syndrome has not posted results as of the most recent public record. That trial is the registered human study most worth monitoring, because it would represent the first controlled human data for any indication.

Until those results appear, BPC-157 is not legal for human therapeutic use in any jurisdiction with a functioning drug authority, it is prohibited in competitive sport, and the evidence base that would justify changing either of those facts does not yet exist. The rodent data is interesting. Interesting rodent data is not a prescription.

[1]: Pharmaceuticals (Basel), 2025. doi:10.3390/ph18020185
[2]: Gut and Liver, 2020. doi:10.5009/gnl18490
[3]: Frontiers in Pharmacology, 2021. doi:10.3389/fphar.2021.627533
[4]: Pharmaceutics, 2026. doi:10.3390/pharmaceutics18050625
[5]: HSS Journal, 2025. doi:10.1177/15563316251355551
[6]: World Journal of Gastrointestinal Pathophysiology, 2020. doi:10.4291/wjgp.v11.i1.1
[7]: Drug Testing and Analysis, 2025. doi:10.1002/dta.3835

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.. Pharmaceuticals (Basel, Switzerland), 2025.

2. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.. Gut and liver, 2020.

3. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.. Frontiers in pharmacology, 2021.

4. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.. Pharmaceutics, 2026.

5. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025.

6. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.. World journal of gastrointestinal pathophysiology, 2020.

7. Annual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024.. Drug testing and analysis, 2025.